Bioxytran Inc (OTCPK:BIXT)
$ 0.090625 -0.00225 (-2.42%) Market Cap: 7.78 Mil Enterprise Value: 8.89 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Bioxytran Inc at Emerging Growth Conference (Virtual) Transcript

Apr 05, 2023 / NTS GMT
Release Date Price: $0.43 (+2.11%)
Ana Berry
Berry Media, Inc - Moderator

Welcome back, everyone. Next up is Bioxytran, Inc. They're on the OTCQB, trading under the ticker symbol BIXT. The company is a clinical-stage biotech with two revolutionary platform technologies. They have an oral glycovirology drug that recently completed clinical trials and achieved 100% viral reduction in seven days.

A feat only accomplished by one other drug in the past decade. Their drug is a galectin inhibitor that neutralizes the COVID-19 virus and prevents it from entering cells. They also have another platform drug being developed to treat strokes. Due to the molecule's small size, it has the ability to carry oxygen into areas of poor circulation.

Now, I did some research, and the JP Morgan conference is like a mecca for big pharma, biotech, investors, and VCs, to meet once a year to share their ideas and network. And every year, they host it in the heart of San Francisco near Union Square, and many even piggyback off the conference with side events nearby.

So this year it looks like over 10,000 people showed up at the JPMorgan

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot